Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 1, 2010, Pages 46-52

  Von Beckerath, Nicolas ^a   Sibbing, Dirk ^a   Jawansky, Stefan ^a   Braun, Siegmund ^a   Morath, Tanja ^a   Vogt, Wolfgang ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adenosine diphosphate; Platelet aggregation; Platelets

Indexed keywords

CLOPIDOGREL; HEMOGLOBIN;

ADULT; ANALYZER; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD ANALYSIS; BYPASS SURGERY; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG MEGADOSE; FAMILY HISTORY; FEMALE; FLOW CYTOMETRY; HEART EJECTION FRACTION; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; AGED; CELL ADHESION MOLECULES; CORONARY ANGIOGRAPHY; ELECTRIC IMPEDANCE; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, PURINERGIC P2; REPRODUCIBILITY OF RESULTS; TICLOPIDINE;

EID: 75649097149     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328332dbd4     Document Type: Article

References (29)

1. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:e166-e286.
2. Steinhubl SR, Charnigo R. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough. JAMA 2006; 295:1581-1582.
3. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schö mig A. Loading with 600mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110:1916-1919.
4. Mü ller I, Besta F, Schulz C, Massberg S, Schö mig A, Gawaz M. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913.
6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45:246-251.
7. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742-1750.
8. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol 2007; 49:2312-2317.
9. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6:54-61.
10. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51:1925-1934.
11. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41:966-968.
12. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008; 28:s33-s38.
13. Bhatt DL. Intensifying platelet inhibition: navigating between Scylla and Charybdis. N Engl J Med 2007; 357:2078-2081.
14. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schö mig A, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99:121-126.
15. Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008; 99:1127-1129.
16. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schö mig A, et al. Platelet reactivity following clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:26-33.
17. Dynabyte Informationssysteme GmbH. Homepage. www.multiplate.net. [Accessed 24 February 2009]
18. Accumetrics Inc. Homepage. http:\\accumetrics.com. [Accessed 24 February 2009]
19. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schö mig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95:910-911.
20. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82:1145-1152.
21. Biocytex. Homepage. http://www.biocytex.fr. [Accessed 24 February 2009]
22. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51:957-965.
23. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4:2516-2518.
24. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5:1839-1847.
25. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
26. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119:237-242.
27. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992-1000.
28. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98:838-843.
29. Oestreich J, Smyth S, Campbell C. Platelet function analysis: at the edge of meaning. doi: 10.1160/TH08-12-0782.